◆英語タイトル：Pancreatic Cancer - Pipeline Review, H1 2020
◆発行会社（リサーチ会社）：Global Markets Direct
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Global Markets Direct社の概要はこちらでご確認いただけます。
Pancreatic Cancer – Pipeline Review, H1 2020
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Pipeline Review, H1 2020, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 199, 207, 2, 8, 363, 57 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 25, 10, 3, 1, 63 and 11 molecules, respectively.
Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Pancreatic Cancer – Overview
Pancreatic Cancer – Therapeutics Development
Pancreatic Cancer – Therapeutics Assessment
Pancreatic Cancer – Companies Involved in Therapeutics Development
Pancreatic Cancer – Drug Profiles
Pancreatic Cancer – Dormant Projects
Pancreatic Cancer – Discontinued Products
Pancreatic Cancer – Product Development Milestones
List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Pancreatic Cancer - Pipeline by 4D Pharma Plc, H1 2020
Pancreatic Cancer - Pipeline by 4SC AG, H1 2020
Pancreatic Cancer - Pipeline by A2 Biotherapeutics Inc, H1 2020
Pancreatic Cancer - Pipeline by AB Science SA, H1 2020
Pancreatic Cancer - Pipeline by AbbVie Inc, H1 2020
Pancreatic Cancer - Pipeline by AbClon Inc, H1 2020
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H1 2020
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020
Pancreatic Cancer - Pipeline by Accendatech Co Ltd, H1 2020
Pancreatic Cancer - Pipeline by Accuronix Therapeutics Inc, H1 2020
Pancreatic Cancer - Pipeline by ACF Pharmaceuticals LLC, H1 2020
Pancreatic Cancer - Dormant Projects, H1 2020
Pancreatic Cancer - Discontinued Products, H1 2020
4D Pharma Plc
A2 Biotherapeutics Inc
AB Science SA
AbGenomics International Inc
Ability Pharmaceuticals SL
Accendatech Co Ltd
Accuronix Therapeutics Inc
ACF Pharmaceuticals LLC
Aclaris Therapeutics Inc
Actuate Therapeutics Inc
Adamed Sp zoo
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Advanz Pharmaceutical Corp Ltd
Advenchen Laboratories LLC
Agency for Science, Technology and Research
Agios Pharmaceuticals Inc
AGV Discovery SAS
AIM ImmunoTech Inc
Alligator Bioscience AB
Allinky Biopharma SL
Almac Discovery Ltd
Altor Bioscience LLC
ALX Oncology Inc
Amplia Therapeutics Ltd
Anavex Life Sciences Corp
Andarix Pharmaceuticals Inc
ANP Technologies Inc
Antapodia Therapeutics Inc
APEIRON Biologics AG
Apexian Pharmaceuticals Inc
Arcus Biosciences Inc
Argonaut Therapeutics Ltd
Asana BioSciences LLC
Ascelia Pharma AB
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
Asclepiumm Taiwan Co Ltd
Asclepius Technology Company Group Suzhou Co Ltd
Astellas Pharma Inc
Augustus BioTarget Inc
AUM Biosciences Pte Ltd
Aurigene Discovery Technologies Ltd
Avenzoar Pharmaceuticals Inc
AVEO Oncology Inc
Basilea Pharmaceutica Ltd
Bausch Health Companies Inc
Bavarian Nordic A/S
Beijing Syngentech Co Ltd
Bellicum Pharmaceuticals Inc
Benhealth Biopharmaceutical (Shenzhen) Co Ltd
Bessor Pharma LLC
Bexion Pharmaceuticals LLC
Bio-Path Holdings Inc
Biokine Therapeutics Ltd
BioMed Valley Discoveries Inc
Biothera Pharmaceutical Inc
BioXcel Therapeutics Inc
BJ Bioscience Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Calidi Biotherapeutics Inc
Cancer Advances Inc
Cancer Prevention Pharmaceuticals Inc
Cancer Vaccines Ltd
Canget BioTekpharma LLC
Cannabis Science Inc
Cantex Pharmaceuticals Inc
CARsgen Therapeutics Ltd
Cascade Prodrug Inc
CCRP Therapeutics GmbH
Celldex Therapeutics Inc
Celleron Therapeutics Ltd
Cellivery Therapeutics Inc
Cello Therapeutics Inc
Cend Therapeutics Inc
Chimeric Therapeutics Ltd
Chiome Bioscience Inc
CHO Pharma Inc
Cloaked Therapeutics LLC
Clovis Oncology Inc
CNS Pharmaceuticals Inc
COARE Biotechnology Inc
COARE Holdings Inc
Codiak BioSciences Inc
Collaborative Medicinal Development LLC
Convert Pharmaceuticals SA
Corcept Therapeutics Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Counterpoint Biomedica LLC
CPL Biologicals Pvt Ltd
Cumberland Pharmaceuticals Inc
CureLab Oncology Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytImmune Sciences Inc